Skip to Main Content

Paper Details

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.
Oncoimmunology
32
2017
-, BCAN, CD4 epitopes, CNS tumors, CSPG4, Gliomas, HLA-A2, IDH1R132H peptide, IGF2BP3, IMA950, IMA950 antigens, PTPRZ1, T cell, TNC proteins, brain tumors, ependymoma, glioblastoma, grade, grade II and III glioma, grade II/III astrocytoma, grade II/III glioma, grade II/III gliomas, mRNA, non, oligodendroglioma, patients, tumor
Author NameAffiliation
Joseph F CostelloBrain Tumor Research Centre, University of California San Francisco
Hideho OkadaBrain Tumor Research Centre, University of California San Francisco
Hideho OkadaUniversity of California San Francisco and The Parker Institute for Cancer Immunotherapy
Christel Herold-MendeUniversity of Heidelberg
  • 1 - 4

Datasets

Release 1.2